1.46

2.82% 0.04

Lineage Cell Therapeutics Inc (LCTX)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.42

Offen:

$1.46

24-Stunden-Volumen:

1.18M

Relative Volume:

0.96

Marktkapitalisierung:

$363.98M

Einnahmen:

$14.56M

Nettoeinkommen (Verlust:

$-63.37M

KGV:

-5.2461

EPS:

-0.2783

Netto-Cashflow:

$-19.44M

1W Leistung:

-6.41%

1M Leistung:

-7.01%

6M Leistung:

-19.78%

1J Leistung:

+218.43%

1-Tages-Spanne:

$1.45

$1.50

1-Wochen-Bereich:

$1.40

$1.58

52-Wochen-Spanne:

$0.425

$2.09

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Firmenname

Lineage Cell Therapeutics Inc

Sektor

Healthcare (1106)

Branche

Biotechnology (615)

Telefon

510-871-4188

Adresse

2173 Salk Avenue, Suite 200, Carlsbad, CA

Mitarbeiter

Twitter

@LineageCell

Nächster Verdiensttermin

2026-05-12

Neueste SEC-Einreichungen

LCTX's Discussions on Twitter

Compare LCTX vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LCTX Lineage Cell Therapeutics Inc	1.46	363.98M	14.56M	-63.37M	-19.44M	-0.2783
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-20	Eingeleitet	Craig Hallum	Buy
2022-11-02	Eingeleitet	Robert W. Baird	Outperform
2022-06-14	Eingeleitet	B. Riley Securities	Buy
2021-08-19	Eingeleitet	Noble Capital Markets	Outperform
2021-03-31	Eingeleitet	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten

May 05, 2026

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update - PharmiWeb.com

May 05, 2026

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - Weekly Voice

May 05, 2026

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) - Weekly Voice

May 05, 2026

May 04, 2026

Lineage Cell Therapeutics Price Target Maintained With a $3.00/Share by D. Boral Capital - Moomoo

May 04, 2026

Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital - Moomoo

May 04, 2026

LCTX Maintained by D. Boral Capital -- Price Target at $3.00 - GuruFocus

May 04, 2026

Lineage Cell Therapeutics presents 3-year Phase 1-2a OpRegen trial results in geographic atrophy at summit - Traders Union

May 04, 2026

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 - Investing News Network

May 04, 2026

3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 - Business Wire

May 04, 2026

Apr 29, 2026

[ARS] Lineage Cell Therapeutics, Inc. SEC Filing - Stock Titan

Apr 29, 2026

Lineage Cell Therapeutics (NYSE American: LCTX) sets 2026 vote on directors, auditor and executive pay - Stock Titan

Apr 29, 2026

Apr 28, 2026

LCTX Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus

Apr 28, 2026

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from Analysts at Canaccord Genuity Group - MarketBeat

Apr 28, 2026

Canaccord Genuity initiates coverage of Lineage Cell Therapeutics (LCTX) with buy recommendation - MSN

Apr 28, 2026

Apr 20, 2026

Lineage (LCTX) Stock Hot Topic (Risk Aversion) 2026-04-20Revenue Growth Stocks - Xã Châu Thành

Apr 20, 2026

Apr 15, 2026

Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration - simplywall.st

Apr 15, 2026

Apr 14, 2026

Lineage Announces Formation of Scientific Advisory Board - BioSpace

Apr 14, 2026

Apr 13, 2026

Lineage Cell Therapeutics (LCTX) Establishes New Scientific Advi - GuruFocus

Apr 13, 2026

Lineage Cell Therapeutics forms advisory board, names clinical head By Investing.com - Investing.com Australia

Apr 13, 2026

Lineage Cell Therapeutics forms advisory board, names clinical head - Investing.com

Apr 13, 2026

Apr 12, 2026

Guidance Update: Can Lineage Cell Therapeutics Inc maintain sales growth2026 Market Trends & Reliable Intraday Trade Alerts - baoquankhu1.vn

Apr 12, 2026

Apr 11, 2026

Tech Rally: Is Lineage Cell Therapeutics Inc still a buy after recent gains2026 Stock Rankings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn

Apr 11, 2026

If You Invested $1,000 in Lineage Cell The (LCTX) - Stock Titan

Apr 11, 2026

Apr 10, 2026

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Finansavisen

Apr 10, 2026

Will Lineage (LCTX) Stock Recover Soon | Price at $1.49, Down 0.34%Chart Patterns - Newser

Apr 10, 2026

Apr 09, 2026

Lineage Cell Therapeutics launches COR1 for corneal diseases amid rising FECD prevalence - Traders Union

Apr 09, 2026

Apr 08, 2026

Q4 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus

Apr 08, 2026

Apr 07, 2026

Pharma News: Can Lineage Cell Therapeutics Inc reach resistance levels soon2026 Technical Overview & AI Enhanced Trading Signals - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Is Lineage (LCTX) Stock Testing Resistance | Price at $1.58, Up 0.64%Investment Community Signals - Newser

Apr 06, 2026

Apr 05, 2026

Lineage Cell Therapeutics pushes scalable platforms to address drug discovery complexity - Traders Union

Apr 02, 2026

Apr 01, 2026